An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects

Trial Profile

An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Fevipiprant (Primary)
  • Indications Liver dysfunction
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 30 May 2017 Planned initiation date changed from 17 May 2017 to 5 Jun 2017.
    • 03 May 2017 Planned End Date changed from 22 Oct 2018 to 30 Jun 2018.
    • 03 May 2017 Planned primary completion date changed from 22 Oct 2018 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top